This is a critical analysis that had a guide the paper published in 2016 "Impact Assessment of Pharmaceutical Care in the Management of Hypertension and Coronary Risk Factors after Discharge". In this manuscript consolidated the clinical results of the Medication Therapy Management (MTM) in the practice of pharmaceutical care. For this it was substantiated to discussion with results of systematic reviews and approached the evidence-based pharmacoeconomic analyses. Regarding important results increase the control of systemic blood pressure from 54% to 93% even after three years of patient discharge. Consequently, there is a 30.3% reduction in cardiovascular risk on the Framingham scale. The Incremental cost-effectiveness analysis ratio is US$ 605.09 in MTM period and US$ 128.03 in post-MTM period, reaching US$ 1,725.00 and US$ 740.00 respectively. It is noteworthy that the resignification of the pharmaceutical profession on the way to resuming clinical practice is essential for improving the effects of this cascade of events that begins in the management of drugs to solve drug-related problems and changes in patient behavior and achieves the longevity regarding greater patient's quality of life. Then this manuscript may supply a gap for professionals in this field regarding the lack of critical citable information for discussing their results in pharmaceutical care research.
